sotorasib (Lumakras)
Jump to navigation
Jump to search
Indications
- treatment of
- non-small cell lung cancer (NSCLC)* or colorectal carcinoma with KRAS p.G12C mutation
* FDA-approved
Dosage
Notes
- KRAS p.G12C mutation is present in 13% of NSCLC & 1-7% of colorectal cancers
More general terms
References
- ↑ Osterweil N Sotorasib Is a 'Triumph of Drug Discovery'in Cancer Medscape - Sep 21, 2020 https://www.medscape.com/viewarticle/937730
Hong DS, Fakih MG, Strickler JH et aL KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020; 383:1207-1217. Sept 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32955176 https://www.nejm.org/doi/full/10.1056/NEJMoa1917239 - ↑ Chustecka Z First Drug for Lung Cancer With KRAS Mutation Gains FDA Approval. Medscape - May 28, 2021. https://www.medscape.com/viewarticle/952091